<?xml version="1.0" encoding="UTF-8"?>
<p id="Par54">The PBRER is very comprehensive, describing post-marketing data, data from completed and ongoing clinical trials, relevant non-interventional studies and other activities, cumulatively and for the specified report period, at a global level. The document also presents a comprehensive and critical analysis of new or emerging information on the risks of the medicinal product in the context of its benefits, taking into account new information from the last reporting period and cumulative information. The analysis of the risks is based on the reference safety information [
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
